en · de · es · fr · pt
glossary-desk.peptides6155.com › Faq › Identity And Research Background — Quick Reference

Identity And Research Background — Quick Reference

By Editorial Desk · published 2026-07-01 · last reviewed 2026-07-29 · Faq

If you have been reading about actin-binding motif and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-07-29. Where a claim depends on a specific study, the study is described rather than over-claimed.

Identity and Research Background

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Identity And Naming Background

Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.

TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.

Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.

Tb-500 at a glance

PropertyValueNotes
Molecular formulaC38H68N10O14Acetylated heptapeptide form
Monoisotopic mass888.5 DaAverage mass about 889 Da
AppearanceWhite to off-white solidUsually supplied as lyophilised powder
Solubility classHighly water solubleAlso dissolves in aqueous buffers
Common synonymsTbeta4 fragment, thymosin beta-4 (17-23)Refer to the same sequence

Handling, Storage, and Analysis

Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.

Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.

Related pages on this site

Handling Storage And Analysis

Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.

Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.

Thymosin Beta-4 Fragment Overview

The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.

TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.

Notes from published material

=== August === 6 August – Tom O'Connor, journalist, author, senior citizens' advocate and local politician, president of Grey Power (2016–2018), Waimate District Councillor (since 2013) (born 1944). 8 August Judy Bailey, pianist, composer, jazz musician and educator (Sydney Conservatorium of Music), and television presenter (Play School) (born 1935). Peter Lester, sailor, sailing coach and commentator, OK dinghy world champion (1977), Admiral's Cup winner (1987, 1993) (born 1954). 10 August – Patrick Waddington, Russian linguist, literary critic and historian (Victoria University of Wellington) (born 1934). 13 August – Grant Tavinor, philosopher (Lincoln University) (born c. 1973). 15 August – John Rowan, lawyer, King's Counsel (since 1997) (born 1944). 16 August – Janet Grieve, biological oceanographer (New Zealand Oceanographic Institute, NIWA), New Zealand Association of Scientists president (1998–2000), World Association of Copepodologists president (2008–2011) (born 1940). 17 August – John Bartley, cinematographer (Lost, The X Files, The Chronicles of Riddick), Emmy Award (1996) (born 1947). 18 August Lloyd Ashby, rugby union player (Southland, national team) (born 1931). Lindsay Sparks, cricketer (Central Districts, Auckland) and rugby union player (Marlborough) (born 1944). 19 August – Tony Smith, legal scholar (University of Reading, University of Cambridge, Victoria University of Wellington) (born 1947). 21 August Evelyn Attwood, tennis player (born 1924). Keith Nelson, rugby union player (Otago, Auckland, national team) and dentist (born 1938).

== Council for Scientific and Industrial Research (CSIR) == Immediately following Prime Minister Billy Hughes' 22 December 1915 "National Laboratory Conference" announcement at a Melbourne University luncheon, the British Science Guild sent the Prime Minister a copy of its (hitherto ignored) 1914 Report, with Robertson's (1913) Report on the Scope and Administration of an Institute for Scientific Research in Australia (BR.13) appended to it. The formal gathering was convened in Melbourne on 5 January 1916; and a Commonwealth Advisory Council of Science and Industry was established, "with over twenty members representing a cross-section of scientific, state, and business interests". On 12 December 1916, the Council's Acting Secretary, Gerald Lightfoot, submitted his Memorandum on the Organization of Scientific Research Institutions in the United States of America (GL.1), to the Council to send on to the Prime Minister. On 14 September 1920, an Institute of Science and Industry, with Sir George Knibbs as its Director, was established by the Institute of Science and Industry Act 1920 (CA.1). On 21 June 1926, the Council for Scientific and Industrial Research (CSIR) was created by the Science and Industry Research Act 1926 (CA.2). The Council consisted of eleven members: three Commonwealth nominees, who formed the Executive Committee (and one of whom would be appointed chairman), and, in addition to the six State chairmen, another two co-opted members.

Legislation comes into force preventing anti-abortion protests within 200 m (656 ft) of clinics where the procedure is carried out. 25 September – ScotRail train drivers belonging to ASLEF have voted to accept a 4.5% pay rise backdated to April, ending their dispute. Scottish comedian Janey Godley reveals she is receiving end-of-life care following the spread of her cancer. 27 September – 2024 Scottish Conservatives leadership election: Russell Findlay is elected as the new leader of the Scottish Conservatives, succeeding Douglas Ross. The scheme that scrapped peak time train fares in Scotland ends after almost a year. 28 September – Charles III marks the 25th anniversary of the establishment of the Scottish Parliament at an event in Edinburgh. Rachael Hamilton is appointed deputy leader of the Scottish Conservatives. 30 September – The minimum unit price of alcohol increases by 30% from 50p per unit to 65p per unit.

Joints are structures that connect individual bones and may allow bones to move against each other to cause movement. There are three divisions of joints: diarthroses, which allow extensive mobility between two or more articular heads; amphiarthroses, which allow some movement; and false joints or synarthroses, which allow little or no movement and are predominantly fibrous. Synovial joints, joints that are not directly joined, are lubricated by a solution called synovial fluid that is produced by the synovial membranes. This fluid lowers the friction between the articular surfaces and is kept within an articular capsule, binding the joint with its taut tissue.

To resolve this dilemma, several mycologists proposed in a 2005 publication to conserve the name Psilocybe, with P. semilanceata as the type. As they explained, conserving the name Psilocybe in this way would prevent nomenclatural changes to a well-known group of fungi, many species of which are "linked to archaeology, anthropology, religion, alternate life styles, forensic science, law enforcement, laws and regulation". Further, the name P. semilanceata had historically been accepted as the lectotype by many authors in the period 1938–68. The proposal to conserve the name Psilocybe, with P. semilanceata as the type was accepted unanimously by the Nomenclature Committee for Fungi in 2009. The mushroom takes its common name from the Phrygian cap, also known as the "liberty cap", which it resembles; P. semilanceata shares its common name with P. pelliculosa, a species from which it is more or less indistinguishable in appearance. The Latin word for Phrygian cap is pileus, nowadays the technical name for what is commonly known as the "cap" of a fungal fruit body. In the 18th century, Phrygian caps were placed on Liberty poles, which resemble the stipe of the mushroom. The generic name is derived from Ancient Greek psilos (ψιλός) 'smooth, bare' and Byzantine Greek kubê (κύβη) 'head'. The specific epithet comes from Latin semi 'half, somewhat' and lanceata, from lanceolatus 'spear-shaped'.

Sources: en.wikipedia.org

Background from the literature

with hypersensitivity to PTH or excipients who have received radiation therapy to the skeleton with pre-existing hypercalcemia and other disturbances in the metabolism of phosphate or calcium with metabolic bone diseases other than primary osteoporosis (including hyperparathyroidism and Paget's disease) with unexplained elevations of bone-specific alkaline phosphatase with severe chronic kidney disease with severe liver impairment

In chemical ionization (CI), the analyte is ionized by a chemical reaction with an ionized reagent gas (itself ionized by some technique, such as by EI). The analyte gas and the reagent gas intersect, and react. The reaction then produces ionized analyte fragments by various mechanisms, including proton transfer, electron transfer, and adduct formation. The ion is then accelerated electrostatically, as in EI. CI ion sources are similar to EI sources, and most modern mass spectrometers can switch from EI to CI mode in minutes. To ensure efficiency, the amount of reagent is much higher than the analyte. Consequently, a large amount of reagent ions would end up in the mass analyzer. This is usually handled by only measuring the part of the spectrogram with m/z above those of the main species in the reagent ion stream. Common ionizing reagents for CI-MS include methane, ammonia, isobutane, and methanol. The proton affinity of the reagent gas and of the sample should be matched to ensure efficient ionization. If the proton affinity of the reagent gas is too high, ionization is inefficient. If the proton affinity of the reagent gas is too low, fragmentation is excessive. For example:

=== Food Safety Management Systems (FSMS) === A Food Safety Management System (FSMS) is "a systematic approach to controlling food safety hazards within a business in order to ensure that the food product is safe to consume." In some countries FSMS is a legal requirement, which obliges all food production businesses to use and maintain a FSMS based on the principles of Hazard Analysis Critical Control Point (HACCP). HACCP is a management system that addresses food safety through the analysis and control of biological, chemical, and physical hazards in all stages of the food supply chain. The ISO 22000 standard specifies the requirements for FSMS.

== Uses == BPF is used in the manufacture of plastics and epoxy resins. It is used in the production of tank and pipe linings, industrial flooring, road and bridge deck toppings, structural adhesives, grouts, coatings and electrical varnishes. BPF is also utilized in liners, lacquers, adhesives, plastics, and the coating of drinks and food cans. BPF is found in dental materials, such as restorative materials, liners, adhesives, oral prosthetic devices and tissue substitutes.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.

What amino acids make up this peptide?

It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.

How much human data exists for this sequence?

Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.

Is TB-500 identical to thymosin beta-4?

No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.

Network